Collectively, we expect that new findings reported here will advance T2D drug discovery in that they emphasize the likely clinical relevance of synthetic dual agonist peptides that simultaneously stimulate the GcgR and GLP-1R (78). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.